Grundläggande statistik
| LEI | 52990044IHUOUMETT163 |
| CIK | 899923 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Myriad Genetics, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| June 4, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 MYRIAD GENETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| June 4, 2026 |
MYRIAD GENETICS, INC. 2026 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN Exhibit 99.1 MYRIAD GENETICS, INC. 2026 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2026 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated |
|
| June 4, 2026 |
MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AGREEMENT – INCORPORATED TERMS AND CONDITIONS Exhibit 99.2 MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AGREEMENT – INCORPORATED TERMS AND CONDITIONS This AGREEMENT (the “Agreement”) made as of the date of grant set forth in the Restricted Stock Unit Award Grant Notice between MYRIAD GENETICS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”). |
|
| June 4, 2026 |
MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN Exhibit 99.1 MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2012 Employee Stock Purchase Plan (the “Plan”) of Myriad Genetics, Inc. (the “Company”). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock o |
|
| June 4, 2026 |
MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AGREEMENT – INCORPORATED TERMS AND CONDITIONS Exhibit 99.3 MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AGREEMENT – INCORPORATED TERMS AND CONDITIONS This AGREEMENT (the “Agreement”) made as of the date of grant set forth in the Restricted Stock Unit Award Grant Notice between MYRIAD GENETICS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”). |
|
| June 4, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 MYRIAD GENETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| June 4, 2026 |
MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN Exhibit 99.1 MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2012 Employee Stock Purchase Plan (the “Plan”) of Myriad Genetics, Inc. (the “Company”). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock o |
|
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 4, 2026 |
MYRIAD GENETICS, INC. 2026 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN Exhibit 99.1 MYRIAD GENETICS, INC. 2026 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2026 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated |
|
| June 4, 2026 |
As filed with the Securities and Exchange Commission on June 4, 2026 As filed with the Securities and Exchange Commission on June 4, 2026 REGISTRATION NO. |
|
| June 4, 2026 |
As filed with the Securities and Exchange Commission on June 4, 2026 As filed with the Securities and Exchange Commission on June 4, 2026 REGISTRATION NO. |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 5, 2026 |
Exhibit 99.1 Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business Highlights •First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. •First quarter 2026 test volume reflects 13% and 7% tes |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| March 4, 2026 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-293681 PROSPECTUS MYRIAD GENETICS, INC. $ 200,000,000 COMMON STOCK PREFERRED STOCK DEPOSITARY SHARES DEBT SECURITIES WARRANTS We may from time to time issue up to $200,000,000 aggregate principal amount of common stock, preferred stock, depositary shares, debt securities and/or warrants. This prospectus provides a general description of the sec |
|
| March 2, 2026 |
Myriad Genetics, Inc. 322 North 2200 West Salt Lake City, UT 84116 Myriad Genetics, Inc. 322 North 2200 West Salt Lake City, UT 84116 March 2, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Myriad Genetics, Inc. Registration Statement on Form S-3 Filed February 24, 2026 File No. 333-293681 (the “Registration Statement”) Acceleration Request Ladies and Ge |
|
| February 27, 2026 |
February 27, 2026 Samraat S. Raha President and Chief Executive Officer Myriad Genetics, Inc. 322 North 2200 West Salt Lake City, UT 84116 Re: Myriad Genetics, Inc. Registration Statement on Form S-3 Filed February 24, 2026 File No. 333-293681 Dear Samraat S. Raha: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 reg |
|
| February 24, 2026 |
Calculation of Filing Fee Tables S-3 MYRIAD GENETICS INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, $0. |
|
| February 24, 2026 |
FIRST AMENDMENT TO CREDIT AGREEMENT Exhibit 10.26 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of January 5, 2026 by and among MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”), and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as administrative agent for the Lenders (in such capacity, and together w |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 24, 2026 |
LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Gateway Genomics, LLC1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH1 Germany Myriad Genetics GmbH 1 Switzerland Myriad Genetics B.V.1 Netherlands Myriad Genetics GK1 Japan 1 – A wholly-owned subsidiary of Myria |
|
| February 24, 2026 |
As filed with the Securities and Exchange Commission on February 24, 2026 As filed with the Securities and Exchange Commission on February 24, 2026 Registration No. |
|
| February 24, 2026 |
Exhibit 4.3 =================================================================== MYRIAD GENETICS, INC. - INDENTURE Dated as of , - DEBT SECURITIES [ ] Trustee =================================================================== Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.0 |
|
| February 23, 2026 |
Exhibit 99.1 Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Highlights •Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million. •Full year 2025 revenue of $824.5 millio |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 12, 2026 |
Exhibit 99.1 Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance SALT LAKE CITY, January 12, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended Decembe |
|
| November 4, 2025 |
Exhibit 99.1 Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights •Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations. •Third quarter 2025 hereditary cancer testing re |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorpora |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 4, 2025 |
EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 14th day of August, 2025 (the “Effective Date”), by and between Myriad Genetics, Inc. |
|
| November 3, 2025 |
Exhibit 99.1 Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights •Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations. •Third quarter 2025 hereditary cancer testing re |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 7, 2025 |
SEPARATION AGREEMENT AND RELEASE OF CLAIMS SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (“Agreement”) is entered into by and between Myriad Genetics, Inc. |
|
| October 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission |
|
| August 18, 2025 |
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer Exhibit 99.1 Myriad Genetics Appoints Ben Wheeler Chief Financial Officer SALT LAKE CITY, August 18, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 20 |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 6, 2025 |
Exhibit 10.4 MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: June 2025) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the “Company,” “our” or “we”) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Direct |
|
| August 5, 2025 |
Exhibit 99.1 Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights •Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year. •Second quarter 2025 hereditary cancer testing revenue and volume in Onc |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 31, 2025 |
Exhibit 10.1 CREDIT AGREEMENT dated as of July 31, 2025 by and among MYRIAD GENETICS, INC., as the Borrower, ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as the Initial Lender, and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as the Administrative Agent TABLE OF CONTENTS Page SECTION 1.1 Defined Terms. 1 SECTION 1.2 Use of Defined Terms 31 SECTION 1.3 Cross-References 31 SECTION 1.4 Accounting |
|
| July 31, 2025 |
Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT This PLEDGE AND SECURITY AGREEMENT, dated as of July 31, 2025 (as amended, supplemented or otherwise modified from time to time, this “Security Agreement”), is made by MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), and the other entities listed on Annex A hereto (together with the Borrower and any other entity that may become party hereto |
|
| July 31, 2025 |
Myriad Genetics Announces New $200 Million Credit Facility Exhibit 99.1 Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facilit |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 5, 2025 |
Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (June 5, 2025) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means the Board of Directors, |
|
| June 5, 2025 |
2017 Employee, Director and Consultant Equity Incentive Plan, as amended MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (June 5, 2025) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means the Board of Directors, |
|
| June 5, 2025 |
Calculation of Filing Fee Tables S-8 MYRIAD GENETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0. |
|
| June 5, 2025 |
As filed with the Securities and Exchange Commission on June 5, 2025 As filed with the Securities and Exchange Commission on June 5, 2025 REGISTRATION NO. |
|
| May 7, 2025 |
Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Performance-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 236,167 5. Vesting Schedule: This Award shall vest on the date of certification by the Administrator of the Achievement (as defined below) of the following milestone st |
|
| May 7, 2025 |
, dated May 1, 2025, by and between t MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Time-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 269,905 5. Vesting Schedule: This Award shall vest as follows provided the Participant is an Employee of, or providing services to, the Company or of an Affiliate on the appli |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 6, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 6, 2025 |
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Exhibit 99.1 Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights •First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year. •First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to Un |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 REGISTRATION NO. |
|
| May 1, 2025 |
Form of Restricted Stock Unit Agreement MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Time-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 269,905 5. Vesting Schedule: This Award shall vest as follows provided the Participant is an Employee of, or providing services to, the Company or of an Affiliate on the appli |
|
| May 1, 2025 |
Form of Performance-Based Restricted Stock Unit Agreement MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Performance-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 236,167 5. Vesting Schedule: This Award shall vest on the date of certification by the Administrator of the Achievement (as defined below) of the following milestone st |
|
| May 1, 2025 |
Calculation of Filing Fee Tables S-8 MYRIAD GENETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0. |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 28, 2025 |
Exhibit 10.6.1 LEASE AGREEMENT This Lease Agreement (the "Lease") is made and entered into effective on the 1st day of December, 2012, (the "Effective Date") by and between the City of Mason, Ohio, an Ohio municipal corporation, 6000 Mason-Montgomery Road, Mason, Ohio 45040 (hereinafter referred to as "Lessor") and AssureRx Health, Inc., a Delaware Corporation, 6030 S. Mason Montgomery Road, Mason |
|
| February 28, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Gateway Genomics, LLC1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH3 Germany Myriad Genetics GmbH 3 Switzerland Myriad Genetics B.V.1 Netherlands Myriad Genetics GK1 Japan 1 |
|
| February 28, 2025 |
Exhibit 19 Purpose The Board of Directors (the “Board”) of Myriad Genetics, Inc. (together with its direct and indirect subsidiaries, the “Company”) has adopted this Insider Trading Policy (this “Policy”), effective as of February 13, 2025. Scope This Policy applies to all trading or other transactions involving or related to Company securities (such as common stock, preferred stock, options to bu |
|
| February 28, 2025 |
Exhibit 10.4.2 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Amendment”) is dated as of this 10th day of April, 2024 (the “Amendment Date”), by and between ATP SLC D, LLC, a Delaware limited liability company (“Lessor”), and MYRIAD GENETICS, INC., a Delaware corporation (“Lessee”). Recitals A.Lessee and Lessor are parties to that certain Lease, dated for reference purposes only a |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 28, 2025 |
Exhibit 10.6.2 FIFTH ADDENDUM TO ASSUREX HEALTH, INC. LEASE AGREEMENT AT 6000 MASON-MONTGOMERY ROAD This Fifth Addendum to Lease Agreement (“Fifth Addendum”) is dated this 20th day of February, 2025 and shall be effective commencing April 1, 2025 between Assurex Health, Inc., a Delaware corporation (“Lessee” and also referred to herein as “Myriad”) and the City of Mason, Ohio, a political subdivis |
|
| February 24, 2025 |
Exhibit 99.1 News Release Media Contact: Kate Schraml Investor Contact: Matt Scalo (224) 875-4493 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth Highlights •Fourth quarter 2024 revenue of $211 mil |
|
| February 24, 2025 |
Amended and Restated Employment Agreement, dated February 2 Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”), made and entered into this 24th day of February, 2025 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Executive”). WHEREAS, Executive currently is employed by Company as its Chief Ope |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 24, 2025 |
, 2025, by and between the Company and Mark S. Verratti. Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 24th day of February, 2025 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Mark S. Verratti (“Executive”). WHEREAS, Executive currently is employed by Company as its Chief Commercial Officer; WHEREAS, following the r |
|
| February 24, 2025 |
Exhibit 99.2 News Release Myriad Genetics Announces Senior Leadership Transition Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 SALT LAKE CITY, February 24, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company’s current Chief Opera |
|
| February 24, 2025 |
, 2025, by and between the Company and Paul J. Diaz. Exhibit 10.5 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is entered into effective as of April 30, 2025 (the “Effective Date”), between Myriad Genetics, Inc. (the “Company”), with a business address at 322 North 2200 West Salt Lake City, Utah 84116, and Paul J. Diaz (the “Consultant”), and governs the Consultant’s services provided to the Company and any of its affiliates as a |
|
| February 24, 2025 |
Exhibit 10.2 SEVERANCE AND CHANGE OF CONTROL AGREEMENT This Severance and Change of Control Agreement (the “Agreement”) is made and entered into on February 24, 2025, by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Employee”). WHEREAS, Employee and the Company previously entered into a Severance and Change of Control Agreement dated December 11, |
|
| February 24, 2025 |
Severance and Change of Control Agreement, dated February 2 Exhibit 10.4 SEVERANCE AND CHANGE OF CONTROL AGREEMENT This Severance and Change of Control Agreement (the “Agreement”) is made and entered into on February 24, 2025, by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Mark S. Verratti (“Employee”). WHEREAS, Employee and the Company previously entered into a Severance and Change of Control Agreement dated October 9, 2 |
|
| February 14, 2025 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2025 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Myriad Genetics, Inc. |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 15, 2025 |
Exhibit 99.1 News Release Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance SALT LAKE CITY, January 15, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended Decembe |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| December 10, 2024 |
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member Exhibit 99.1 News Release Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member SALT LAKE CITY, December 10, 2024 - Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective immediately, expanding the Board from eight to nine members. Additionally, Da |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2024 |
MYGN / Myriad Genetics, Inc. / GLENVIEW CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 sc13gano2mygn.htm SC 13G/A 1 sayw2402142513ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Myriad Genetics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 62855J104 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 7, 2024 |
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance Highlights •Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on pa |
|
| November 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 6, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| August 6, 2024 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% Highlights •Second quarter revenue grew 15% year-o |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 3, 2024 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE MYRIAD GENETICS, INC. STOCKHOLDER DERIVATIVE LITIGATION ) ) C.A. No. 2021-0686-SG NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE LITIGATION TO: ALL CURRENT STOCKHOLDERS OF MYRIAD GENETICS, INC. (NASDAQ SYMBOL: MYGN) PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS WILL BE AFFECTED BY THE LEGAL PROCEEDINGS IN THI |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 3, 2024 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE MYRIAD GENETICS, INC. STOCKHOLDER DERIVATIVE LITIGATION ) ) C.A. No. 2021-0686-SG STIPULATION OF SETTLEMENT This Stipulation of Settlement (“Stipulation”) is made and entered into as of April 30, 2024, between and among, (a)(i) plaintiffs Donna Hickok (“Hickok”) and Leo Shumacher (“Shumacher”) in the above-captioned consolidated derivative ac |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 7, 2024 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: •First quarter revenue of $2 |
|
| May 1, 2024 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 MYGNSC13GMay2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) APRIL 25, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designat |
|
| April 25, 2024 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 MYGNSC13GApril2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) APRIL 17, 2024 (Date of event which requires filing of this statement) Check the appropriate box to design |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| March 18, 2024 |
MYGN / Myriad Genetics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) MARCH 12, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 28, 2024 |
etween Myriad Women's Health, Inc. and Bayside Area Development, LLC. Exhibit 10.5 NEXUS ON GRAND LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company ("Landlord"), and MYRIAD GENETICS, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTION 1 |
|
| February 28, 2024 |
Exhibit 10.19 SEPARATION AND CONSULTING AGREEMENT AND RELEASE OF CLAIMS This Separation and Consulting Agreement and Release of Claims (“Agreement”), dated as of October 4, 2023, is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Nicole Lambert (“Executive” and together with the Company, the “Parties” and eac |
|
| February 28, 2024 |
Exhibit 10.17 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 15th day of December, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Scott Leffler (“Executive”). WHEREAS, the Company wishes to employ Executive as its Chief Financial Officer; WHEREAS, Executive represents t |
|
| February 28, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Gateway Genomics, LLC1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH4 Germany Myriad Services GmbH3 Germany Myriad Genetics Espana SL1 Spain Myriad Genetics SAS3 France Myriad |
|
| February 28, 2024 |
dated February 9, 2022, between Myriad Genetics, Inc. and Bay Bridge/Corporate, LLC. Exhibit 10.4 Building D LEASE 322 North 2200 West (Building D) Salt Lake City, Utah LESSOR: BAY BRIDGE/CORPORATE, LLC LESSEE: MYRIAD GENETICS, INC. Building D TABLE OF CONTENTS Page Section 1 PARTIES 1 Section 2 PREMISES 1 2.1 Premises 1 2.2 Common Areas 3 Section 3 TERM 6 3.1 Term 6 3.2 Termination Right 7 Section 4 RENT 7 4.1 Monthly Basic Rent 7 4.2 Additional Charges 8 4.3 Net Lease 9 Section |
|
| February 28, 2024 |
ease Termination Agreement, dated December 18, 2023, between the R Exhibit 10.1.3 EXECUTION VERSION LEASE TERMINATION AGREEMENT (Myriad Genetics: Phase I) THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of the 18th day of December, 2023 (the “Effective Date”) by and between HCPI/UTAH II, LLC, a Delaware limited liability company (“Landlord”) and MYRIAD GENETICS, INC., a Delaware corporation (“Tenant”) (each a “Party” and collectively the “P |
|
| February 28, 2024 |
Exhibit 10.3.3 EXECUTION VERSION LEASE TERMINATION AGREEMENT (Myriad Genetics: Phase III) THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of the 18th day of December, 2023 (the “Effective Date”) by and between HCPI/UTAH II, LLC, a Delaware limited liability company (“Landlord”) and MYRIAD GENETICS, INC., a Delaware corporation (“Tenant”) (each a “Party” and collectively the |
|
| February 28, 2024 |
ease Termination Agreement, dated December 18, 2023, between Exhibit 10.2.3 EXECUTION VERSION LEASE TERMINATION AGREEMENT (Myriad Genetics: Phase II) THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of the 18th day of December, 2023 (the “Effective Date”) by and between HCPI/UTAH II, LLC, a Delaware limited liability company (“Landlord”) and MYRIAD GENETICS, INC., a Delaware corporation (“Tenant”) (each a “Party” and collectively the “ |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 28, 2024 |
, by and between Myriad Genetics, Inc. and Samraat S. Raha+ Exhibit 10.16 SEVERANCE AND CHANGE OF CONTROL AGREEMENT This Severance and Change of Control Agreement (the “Agreement”) is made and entered into on December 11, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Employee”). WHEREAS, Employee is currently employed by the Company under the terms of a separate employment a |
|
| February 28, 2024 |
Exhibit 97.1 CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of Myriad Genetics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this policy |
|
| February 28, 2024 |
ration and Consulting Agreement and Release of Claims, dated December 15, 2023 Exhibit 10.18 SEPARATION AND CONSULTING AGREEMENT AND RELEASE OF CLAIMS This Separation and Consulting Agreement and Release of Claims (“Agreement”), dated as of December 15, 2023, is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and R. Bryan Riggsbee (“Executive” and together with the Company, the “Parties” an |
|
| February 27, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 27, 2024 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS o |
|
| February 14, 2024 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment SC 13G/A 1 CamberMYGN13Ga2024.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2024 |
MYGN / Myriad Genetics, Inc. / GLENVIEW CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 sayw2402142513ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Myriad Genetics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the app |
|
| February 14, 2024 |
EX-1 2 CamberMYGN-13Ga2024ex1.htm JOINT FILLING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2024 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securiti |
|
| February 13, 2024 |
MYGN / Myriad Genetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01504-myriadgeneticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Myriad Genetics Inc Title of Class of Securities: Common Stock CUSIP Number: 62855J104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desig |
|
| February 8, 2024 |
MYGN / Myriad Genetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Myriad Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62855J104 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 24, 2024 |
MYGN / Myriad Genetics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 MyriadGeneticsInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING MYRIAD GENETICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 62855J104 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURS |
|
| January 23, 2024 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rul |
|
| January 22, 2024 |
MYGN / Myriad Genetics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us62855j1043012224.txt us62855j1043012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) MYRIAD GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 62855J104 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 16, 2024 |
©2024 Myriad Genetics, Inc. 42nd Annual J.P. Morgan Healthcare Conference J A N U A R Y 1 0 , 2 0 2 4 ©2024 Myriad Genetics, Inc. ©2024 Myriad Genetics, Inc. Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are |
|
| January 16, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| December 21, 2023 |
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance SALT LAKE CITY, Dec. |
|
| November 13, 2023 |
Exhibit 1.1 Myriad Genetics, Inc. Common Stock Underwriting Agreement November 8, 2023 Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, Wells Fargo Securities, LLC, As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282 c/o Morgan Stanley & Co. LLC, 1585 Broadway New York, New York |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 13, 2023 |
6,470,588 Shares Myriad Genetics, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275396 Prospectus Supplement (To Prospectus dated November 8, 2023) 6,470,588 Shares Myriad Genetics, Inc. Common Stock We are offering 6,470,588 shares of our common stock, par value $0.01 per share. Our common stock is listed on The Nasdaq Global Select Market under the trading symbol “MYGN.” On November 8, 2023, the last reported sale price |
|
| November 13, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) MYRIAD GENETICS, INC. |
|
| November 9, 2023 |
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock Salt Lake City, Utah, November 8, 2023 – Myriad Genetics, Inc. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 8, 2023 |
Form of Indenture for debt securities between the registrant and the trustee to be named therein. Exhibit 4.3 =================================================================== MYRIAD GENETICS, INC. - INDENTURE Dated as of , - DEBT SECURITIES [ ] Trustee =================================================================== Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.0 |
|
| November 8, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275396 The information in this preliminary prospectus supplement is not complete and may be changed. Neither this preliminary prospectus supplement nor the accompanying prospectus is an offer to sell these securities nor does it solicit offers to buy these securities in any jurisdiction where such offer or sale is not permitted. Subject to Comp |
|
| November 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Myriad Genetics, Inc. |
|
| November 8, 2023 |
As filed with the Securities and Exchange Commission on November 8, 2023 As filed with the Securities and Exchange Commission on November 8, 2023 Registration No. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 7, 2023 |
, between Myriad Genetics, Inc. and Samraat S. Raha+ Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 17th day of October, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Executive”). WHEREAS, the Company wishes to employ Executive as its Chief Operating Officer; WHEREAS, Executive represents t |
|
| November 6, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance Highlights: •Third quarter testing volume grew 18% year-over-year, exclu |
|
| November 6, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 1, 2023 |
Press Release, Dated November 1, 2023 Myriad Genetics Appoints Sam Raha as Chief Operating Officer SALT LAKE CITY, Nov. 1, 2023 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023. Raha adds more than 25 years of general management, commercial, and operations experience, deeply rooted in li |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 31, 2023 |
FIRST AMENDMENT TO CREDIT AGREEMENT AND PLEDGE AND SECURITY AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND PLEDGE AND SECURITY AGREEMENT (this “Amendment”), dated as of October 31, 2023, is among MYRIAD GENETICS, INC. |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 17, 2023 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 MYGNSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) OCTOBER 10, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 5, 2023 |
Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT AND RELEASE OF CLAIMS This Separation and Consulting Agreement and Release of Claims (“Agreement”), dated as of October 4, 2023, is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Nicole Lambert (“Executive” and together with the Company, the “Parties” and each |
|
| August 4, 2023 |
Restated Certificate of Incorporation, as amended mgirestatedcertificateof PAGE 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS FILED FROM AND INCLUDING THE RESTATED CERTIFICATE OR A MERGER WITH A RESTATED CERTIFICATE ATTACHED OF “MYRIAD GENETICS, INC. “ AS RECEIVED AND FILED IN THIS OFFICE. THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED: RESTATED CERTI |
|
| August 4, 2023 |
Non-Employee Director Compensation Policy Exhibit 10.4 MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: June 2023) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the “Company,” “our” or “we”) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Direct |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 3, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth Highlights: •Second quarter t |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 6, 2023 |
myriadgeneticsannouncesn Myriad Genetics Announces New $90 Million Asset-Based Credit Facility SALT LAKE CITY, July 6, 2023 –Myriad Genetics, Inc. |
|
| July 6, 2023 |
Exbibit 10.2 PLEDGE AND SECURITY AGREEMENT THIS PLEDGE AND SECURITY AGREEMENT (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) is entered into as of June 30, 2023 by and among MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), MYRIAD GENETICS LABORATORIES, INC., a Delaware corporation, MYRIAD WOMEN’S |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 6, 2023 |
Exhibit 10.1 CREDIT AGREEMENT dated as of June 30, 2023 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Joint Bookrunners and Joint Lead Arrangers ASSET BASED LENDING TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. Classific |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 2, 2023 |
Certificate of Amendment to Restated Certificate of Incorporation, as amended, dated June 1, 2023 certificateofamendmentex |
|
| June 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Myriad Genetics, Inc. |
|
| June 1, 2023 |
2017 Employee, Director and Consultant Equity Incentive Plan, as amended MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (June 1, 2023) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means the Board of Directors, |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 As filed with the Securities and Exchange Commission on June 1, 2023 REGISTRATION NO. |
|
| May 4, 2023 |
Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan (Employee). MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AGREEMENT - INCORPORATED TERMS AND CONDITIONS This AGREEMENT (the “Agreement”) made as of the date of grant set forth in the Restricted Stock Unit Award Grant Notice between MYRIAD GENETICS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”). WHEREAS, the |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 3, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 3, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range Highlig |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 12, 2023 |
mygn-20221231xars412 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| March 1, 2023 |
MYGN / Myriad Genetics, Inc. / GLENVIEW CAPITAL MANAGEMENT, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Myriad Genetics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 62855J104 (CUSIP Number) February 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| March 1, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Gateway Genomics, LLC1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH4 Germany Myriad Services GmbH3 Germany Myriad Genetics Espana SL1 Spain Myriad Genetics SAS3 France Myriad |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 28, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes Highlights: •Fourth quarter t |
|
| February 14, 2023 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment SC 13G/A 1 camberMYGN13Ga2023.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2023 |
EX-1 2 camberMYGN-13Ga2023ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2023 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securitie |
|
| February 9, 2023 |
MYGN / Myriad Genetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01470-myriadgeneticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Myriad Genetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 62855J104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desi |
|
| February 6, 2023 |
MYGN / Myriad Genetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Myriad Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62855J104 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 31, 2023 |
MYGN / Myriad Genetics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 MyriadGeneticsInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING MYRIAD GENETICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 62855J104 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURS |
|
| January 23, 2023 |
MYGN / Myriad Genetics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us62855j1043012323.txt us62855j1043012323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) MYRIAD GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 62855J104 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 9, 2023 |
SC 13G/A 1 mygn13g2nd1222.txt MYRIAD GENETICS, INC. - 12/31/2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2) MYRIAD GENETICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 62855J104 - (CUSIP Number) 12/31/2022 - (Date of Event Which Requires Filing of this Statement) Check th |
|
| November 2, 2022 |
Non-Employee Director Compensation Policy+ MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: September 2022) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the “Company,” “our” or “we”) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Directors (the |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 1, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 1, 2022 |
Myriad Genetics Reports Third Quarter Financial Results Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Third Quarter Financial Results Highlights: ?Revenue of $156.4 million for the quarter ended September 30, 2022. ?Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 mil |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 4, 2022 |
Myriad Genetics Reports Second Quarter Financial Results Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Foster Harris (385) 318-3718 (385) 350-8015 [email protected] [email protected] Myriad Genetics Reports Second Quarter Financial Results Highlights: ?Revenue of $179.3 million for the quarter ended June 30, 2022 ?Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially |
|
| August 4, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 27, 2022 |
EXECUTION VERSION AMENDMENT NO. 4 dated as of July 26, 2022 to CREDIT AGREEMENT Dated as of December 23, 2016 THIS AMENDMENT NO. 4 (?Amendment?), dated as of July 26, 2022 (the ?Effective Date?), is entered into by and among MYRIAD GENETICS, INC., a Delaware corporation (the ?Borrower?), the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent (the ?Administrative Agent?). |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 6, 2022 As filed with the Securities and Exchange Commission on June 6, 2022 REGISTRATION NO. |
|
| June 6, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Myriad Genetics, Inc. |
|
| June 2, 2022 |
Amended and Restated 2012 Employee Stock Purchase Plan Exhibit 10.1 MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2012 Employee Stock Purchase Plan (the ?Plan?) of Myriad Genetics, Inc. (the ?Company?). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock o |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 12, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated May 12, 2022 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| May 12, 2022 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) May 02, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 5, 2022 |
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022 Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Nathan Smith (315) 730-2379 (801) 505-5067 [email protected] [email protected] Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022 Highlights: ?Revenue of $164.9 million for the quarter ended March 31, 2022 ?Excluding revenue from divested businesses, revenue increased 11% year-over-yea |
|
| May 5, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| February 25, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Myriad Women?s Health, Inc1 Delaware Myriad GmbH4 Germany Myriad Services GmbH3 Germany Myriad Genetics Espana SL1 Spain Myriad Genetics SAS3 France Myriad Genetics S.r.l.1 Italy Myriad G |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 24, 2022 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Nathan Smith (315) 730-2379 (801) 505-5067 [email protected] [email protected] Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives Highlights: ?Strong business performance despite COVID-19 headwinds ?Revenue of $160.8 million in the fourth quarter an |
|
| February 24, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2022 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 14, 2022 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 11, 2022 |
MYGN / Myriad Genetics, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING MYRIAD GENETICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 62855J104 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FI |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1) MYRIAD GENETICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 62855J104 - (CUSIP Number) 12/31/2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2022 |
MYGN / Myriad Genetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Myriad Genetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 62855J104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2022 |
Consulting Agreement, dated February 7, 2022, by and between Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT This Separation and Consulting Agreement (?Agreement?), dated as of February 7, 2022, is entered into between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the ?Company?), and Jerry Lanchbury (?Employee? and, together with the Company, the ?Parties? and each a ?Party?). WHEREAS, Employee is employed by th |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 4, 2022 |
MYGN / Myriad Genetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Myriad Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 27, 2022 |
MYGN / Myriad Genetics, Inc. / BlackRock Inc. Passive Investment us62855j1043012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) MYRIAD GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 62855J104 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 26, 2022 |
MYGN / Myriad Genetics, Inc. / BlackRock Inc. Passive Investment us62855j1043012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) MYRIAD GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 62855J104 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 11, 2022 |
Illuminating the path to better health through genetic insights 40th Annual J.P. Morgan Health Care Conference January 11, 2022 Paul J. Diaz President and CEO Myriad Genetics ?2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 2 Forward looking statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or |
|
| January 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 14, 2021 |
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer SALT LAKE CITY, Dec. |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| November 4, 2021 |
Amended and Restated 2012 Employee Stock Purchase Plan+ Exhibit 10.1 MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2012 Employee Stock Purchase Plan (the ?Plan?) of Myriad Genetics, Inc. (the ?Company?). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock o |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 2, 2021 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Nathan Smith (315) 730-2379 (801) 505-5067 [email protected] [email protected] Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans Highlights: ?Revenue of $167.3 million up 15% year-over-year. Excluding revenue from divested businesses, revenue |
|
| November 2, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 3, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| August 3, 2021 |
Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Nathan Smith (801) 505-5027 (801) 505-5067 [email protected] [email protected] Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans SALT LAKE CITY, August 3, 2021 ? Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic tes |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 24, 2021 |
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Nathan Smith (801) 505-5027 (801) 505-5067 [email protected] [email protected] Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions SALT LAKE CITY, May 24, 2021 ? Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitiv |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 3, 2021 |
Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 [email protected] [email protected] Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives Highlights: ?Revenue of $173.1 million increases 12% sequentially ?GAAP earnings per share of $(0.52), adjus |
|
| May 3, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 15, 2021 |
DEFA14A 1 defa14a-2021proxyadditiona.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio |
|
| March 16, 2021 |
Non-Employee Director Compensation Policy+ MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: Fiscal Year 2021) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the ?Company,? ?our? or ?we?) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Directors (t |
|
| March 16, 2021 |
DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Myriad Genetics, Inc. |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from July 1, 2020 to December 31, 2020 Commission file number: 0-26642 MYRIAD GENETICS, INC. (Exact nam |
